5-Amino-1MQ for fat loss: What the science actually shows
Quick answer
5-Amino-1MQ is an experimental small molecule NNMT inhibitor with demonstrated fat-reducing effects in obese mouse models, primarily through proposed effects on NAD+ precursor availability and adipose tissue metabolism. No human clinical trials have been completed or published as of early 2025, and no regulatory body has approved it for any therapeutic use. Its off-target effects on methylation biology and long-term safety profile in humans remain unknown.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @jleeactive actually say?
The creator described 5-amino-1MQ as a small molecule NNMT inhibitor, not a peptide, that works by preserving the methyl groups and precursors your body uses to make NAD+. The core claim: block NNMT, NAD+ rises, and you get better fat metabolism, improved insulin sensitivity, and more efficient energy use inside cells. They also stated, correctly, that "there are no human trials yet" and called it "experimental."
They added anecdotal claims from their own cutting phase and from others during both fat loss and muscle gaining phases. The framing is relatively restrained for TikTok, leaning on research models rather than promising transformation. That restraint is worth noting, because it changes how we evaluate the claims below.
Does the science back this up?
The rodent data is real, and it is genuinely interesting. The mechanistic story the creator tells is mostly accurate. The leap to human application, though, is significant and not yet supported.
Nawaz et al. (2021, Nature Communications) showed that 5-amino-1MQ reduced fat mass in diet-induced obese mice without altering food intake, which directly matches what the creator described. The proposed mechanism, NNMT inhibition freeing up SAM (S-adenosylmethionine) to support NAD+ biosynthesis, is supported by earlier mechanistic work from Kraus et al. (2014, Nature Medicine), which established NNMT as a regulator of adipose tissue metabolism. So the foundational science is legitimate.
What we do not have: any randomized controlled trial in humans, any dose-ranging safety study in humans, or pharmacokinetic data showing oral or injectable 5-amino-1MQ behaves the same way in humans as in rodent models. That is not a minor gap. Rodent-to-human translation in metabolic research fails more often than it succeeds.
What did they get wrong (or right)?
A few things deserve specific attention, some positive, some not.
- Correctly identified: 5-amino-1MQ is not a peptide. The creator explicitly corrects this common mislabeling. That is accurate and worth credit. It is a small molecule NNMT inhibitor, and conflating it with peptides creates regulatory and safety confusion.
- Mostly accurate: The NNMT enzyme description is roughly correct, though technically NNMT methylates nicotinamide (a form of B3) using SAM, converting it to 1-methylnicotinamide and depleting SAM in the process. The creator simplified this as NNMT "breaking down vitamin B3," which is imprecise but not wildly wrong for a TikTok audience.
- Misleading framing: Saying "anecdotally, we've seen people getting great results" after correctly flagging no human trials is a rhetorical move that undermines the disclaimer. Anecdote is not data, and stacking personal success stories onto experimental-only evidence nudges viewers toward use without adequate warning.
- Missing safety context: No mention of unknown off-target methylation effects, which are a legitimate concern with systemic NNMT inhibition. No mention of sourcing risks for unregulated research chemicals.
What should you actually know?
If you are a healthy adult considering 5-amino-1MQ because a fitness creator had "some success" during a cut, here is the honest picture.
The mechanism is scientifically plausible. The rodent evidence is encouraging enough that researchers are pursuing it. But plausible mechanisms and mouse studies have produced a long list of metabolic compounds that failed or caused harm in humans. Resveratrol and many NAD+ precursor strategies looked equally promising at this stage.
There is no established safe dose for humans. There is no long-term safety data. NNMT plays roles beyond fat metabolism, including in liver function and potentially in certain cancer biology, so blocking it systemically is not a trivial intervention. This is a research chemical sold through gray-market channels, which introduces real contamination and dosing accuracy concerns entirely separate from the pharmacology.
Consult a licensed clinician before considering any unapproved compound. The fact that something is sold as a "research chemical" does not make it low-risk.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For 5-Amino-1MQ for fat loss: What the science actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
5-Amino-1MQ for fat loss: What the science actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
5-Amino-1MQ is an experimental small molecule NNMT inhibitor with demonstrated fat-reducing effects in obese mouse models, primarily through proposed effects on NAD+ precursor availability and adipose tissue metabolism.
FormBlends verdict
5-Amino-1MQ is an experimental small molecule NNMT inhibitor with demonstrated fat-reducing effects in obese mouse models, primarily through proposed effects on NAD+ precursor availability and adipose tissue metabolism. No human clinical trials have been completed or published as of early 2025, and no regulatory body has approved it for any therapeutic use. Its off-target effects on methylation biology and long-term safety profile in humans remain unknown.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- 5-Amino-1MQ is an experimental small molecule NNMT inhibitor with demonstrated fat-reducing effects in obese mouse models, primarily through proposed effects on NAD+ precursor availability and adipose tissue metabolism. No human clinical trials have been completed or published as of early 2025, and no regulatory body has approved it for any therapeutic use. Its off-target effects on methylation biology and long-term safety profile in humans remain unknown.
- Nawaz et al. (2021, Nature Communications) confirmed fat mass reduction in obese mice given 5-amino-1MQ without dietary changes, making the rodent evidence real but not yet human-applicable.
- NNMT inhibition works by preserving SAM pool availability for NAD+ biosynthesis, not by directly blocking B3 breakdown. The distinction matters for understanding potential off-target methylation effects.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Nawaz et al. (2021, Nature Communications) confirmed fat mass reduction in obese mice given 5-amino-1MQ without dietary changes, making the rodent evidence real but not yet human-applicable.
- NNMT inhibition works by preserving SAM pool availability for NAD+ biosynthesis, not by directly blocking B3 breakdown. The distinction matters for understanding potential off-target methylation effects.
- Zero completed human clinical trials exist for 5-amino-1MQ. Rodent-to-human translation in metabolic drug development has a poor historical success rate.
- NNMT has documented roles in liver biology and has been studied in cancer contexts. Systemic inhibition in humans carries unknown risks that no current safety data can address.
- 5-amino-1MQ is sold as a research chemical through unregulated channels, meaning purity, actual dosage, and contamination cannot be guaranteed by the buyer.
- The creator correctly identified that this compound is not a peptide, a distinction that matters because regulatory and safety assumptions around peptides do not apply here.
- No licensed clinician should be replaced by a TikTok anecdote. Anyone considering experimental compounds should get baseline labs and work with a qualified provider who can monitor relevant biomarkers.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
jleeactive · TikTok creator
29.0K views on this video
5 Amino 1MQ. I had some success with this when I was in my previous cut and needed that little extra. ⚒️Coaching & Consults: JLEEACTIVE.com 🩸 Get Labs: @mandmlabs_ My Custom Labs (Code: jleeactive) *or build your own panels. 🧪 Research Products & Medical Supplies: Solo.to (Link in Bio) Affiliates & Amazon Store #fitness #motivation #hormones
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by jleeactive, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.